Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 is sensitive to type I interferon pretreatment

Kumari G. Lokugamage, View ORCID ProfileAdam Hage, View ORCID ProfileCraig Schindewolf, View ORCID ProfileRicardo Rajsbaum, View ORCID ProfileVineet D. Menachery
doi: https://doi.org/10.1101/2020.03.07.982264
Kumari G. Lokugamage
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Hage
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam Hage
Craig Schindewolf
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Craig Schindewolf
Ricardo Rajsbaum
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
2Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ricardo Rajsbaum
Vineet D. Menachery
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
2Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vineet D. Menachery
  • For correspondence: Vimenach@utmb.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Article Information

doi 
https://doi.org/10.1101/2020.03.07.982264
History 
  • April 9, 2020.

Article Versions

  • Version 1 (March 9, 2020 - 17:54).
  • Version 2 (March 18, 2020 - 02:48).
  • You are currently viewing Version 3 of this article (April 9, 2020 - 17:06).
  • View Version 4, the most recent version of this article.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Kumari G. Lokugamage1,
  2. Adam Hage1,
  3. Craig Schindewolf1,
  4. Ricardo Rajsbaum1,2 and
  5. Vineet D. Menachery1,2,*
  1. 1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA
  2. 2Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston TX, USA
  1. ↵*Corresponding Author:
    Vineet D. Menachery, Address:
    University of Texas Medical Branch, 301 University Blvd, Route #0610 Galveston, TX 77555, Email:
    Vimenach{at}utmb.edu
Back to top
PreviousNext
Posted April 09, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 is sensitive to type I interferon pretreatment
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 is sensitive to type I interferon pretreatment
Kumari G. Lokugamage, Adam Hage, Craig Schindewolf, Ricardo Rajsbaum, Vineet D. Menachery
bioRxiv 2020.03.07.982264; doi: https://doi.org/10.1101/2020.03.07.982264
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 is sensitive to type I interferon pretreatment
Kumari G. Lokugamage, Adam Hage, Craig Schindewolf, Ricardo Rajsbaum, Vineet D. Menachery
bioRxiv 2020.03.07.982264; doi: https://doi.org/10.1101/2020.03.07.982264

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4838)
  • Biochemistry (10750)
  • Bioengineering (8020)
  • Bioinformatics (27205)
  • Biophysics (13945)
  • Cancer Biology (11088)
  • Cell Biology (16004)
  • Clinical Trials (138)
  • Developmental Biology (8760)
  • Ecology (13250)
  • Epidemiology (2067)
  • Evolutionary Biology (17325)
  • Genetics (11667)
  • Genomics (15888)
  • Immunology (10999)
  • Microbiology (26007)
  • Molecular Biology (10612)
  • Neuroscience (56379)
  • Paleontology (417)
  • Pathology (1729)
  • Pharmacology and Toxicology (2999)
  • Physiology (4530)
  • Plant Biology (9593)
  • Scientific Communication and Education (1610)
  • Synthetic Biology (2674)
  • Systems Biology (6961)
  • Zoology (1508)